J Kay

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint The role of interleukin-1 in the pathogenesis of rheumatoid arthritis
    J Kay
    Rheumatology Unit, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Rheumatology (Oxford) 43:iii2-iii9. 2004
  2. ncbi request reprint Imatinib mesylate treatment of nephrogenic systemic fibrosis
    Jonathan Kay
    Rheumatology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Arthritis Rheum 58:2543-8. 2008
  3. doi request reprint Nephrogenic systemic fibrosis: a new concern for rheumatologists
    Jonathan Kay
    Nat Clin Pract Rheumatol 4:445. 2008
  4. doi request reprint Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin
    Jonathan Kay
    Department of Medicine, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, USA
    N Engl J Med 358:827-38. 2008
  5. doi request reprint Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction
    J Kay
    Division of Rheumatology, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
    Ann Rheum Dis 67:iii66-9. 2008
  6. doi request reprint Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study
    Jonathan Kay
    Rheumatology Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114, USA
    Arthritis Rheum 58:964-75. 2008
  7. doi request reprint A rheumatology-specific informatics-based application with a disease activity calculator
    Deborah S Collier
    Massachusetts General Hospital, Boston, MA, USA
    Arthritis Rheum 61:488-94. 2009
  8. doi request reprint Physician ability to assess rheumatoid arthritis disease activity using an electronic medical record-based disease activity calculator
    Deborah S Collier
    Massachusetts General Hospital, Boston, MA, USA
    Arthritis Rheum 61:495-500. 2009
  9. ncbi request reprint Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure
    Derrick J Todd
    Massachusetts General Hospital, Harvard Medical School, and Brigham and Women s Hospital, Boston, Massachusetts 02114, USA
    Arthritis Rheum 56:3433-41. 2007
  10. ncbi request reprint Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients
    Hani H Abujudeh
    Department of Radiology and Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Radiology 253:81-9. 2009

Detail Information

Publications21

  1. ncbi request reprint The role of interleukin-1 in the pathogenesis of rheumatoid arthritis
    J Kay
    Rheumatology Unit, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Rheumatology (Oxford) 43:iii2-iii9. 2004
    ..Taken together, these results indicate that IL-1 plays an important role in the pathogenesis of RA...
  2. ncbi request reprint Imatinib mesylate treatment of nephrogenic systemic fibrosis
    Jonathan Kay
    Rheumatology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Arthritis Rheum 58:2543-8. 2008
    ..To examine the effectiveness of imatinib mesylate in the treatment of nephrogenic systemic fibrosis (NSF)...
  3. doi request reprint Nephrogenic systemic fibrosis: a new concern for rheumatologists
    Jonathan Kay
    Nat Clin Pract Rheumatol 4:445. 2008
  4. doi request reprint Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin
    Jonathan Kay
    Department of Medicine, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, USA
    N Engl J Med 358:827-38. 2008
  5. doi request reprint Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction
    J Kay
    Division of Rheumatology, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
    Ann Rheum Dis 67:iii66-9. 2008
    ..Although no medical treatment has been proved to be universally effective in patients with NSF, imatinib mesylate shows potential as a therapeutic agent and is currently being studied in these patients...
  6. doi request reprint Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study
    Jonathan Kay
    Rheumatology Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114, USA
    Arthritis Rheum 58:964-75. 2008
    ..To assess the efficacy, safety, and pharmacology of subcutaneous administration of golimumab in patients with active rheumatoid arthritis (RA) despite treatment with methotrexate (MTX)...
  7. doi request reprint A rheumatology-specific informatics-based application with a disease activity calculator
    Deborah S Collier
    Massachusetts General Hospital, Boston, MA, USA
    Arthritis Rheum 61:488-94. 2009
    ..To design a rheumatology-specific tool with a disease activity calculator integrated into the electronic medical records (EMRs) at our institution and assess physicians' attitudes toward the use of this tool...
  8. doi request reprint Physician ability to assess rheumatoid arthritis disease activity using an electronic medical record-based disease activity calculator
    Deborah S Collier
    Massachusetts General Hospital, Boston, MA, USA
    Arthritis Rheum 61:495-500. 2009
    ..To assess physicians' concordance with Disease Activity Score in 28 joints (DAS28) categories calculated by an electronic medical record (EMR)-embedded disease activity calculator, as well as attitudes toward this application...
  9. ncbi request reprint Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure
    Derrick J Todd
    Massachusetts General Hospital, Harvard Medical School, and Brigham and Women s Hospital, Boston, Massachusetts 02114, USA
    Arthritis Rheum 56:3433-41. 2007
    ..Little is known about its prevalence or etiology. The aim of this study was to establish the prevalence of NSF and associated risk factors..
  10. ncbi request reprint Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients
    Hani H Abujudeh
    Department of Radiology and Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Radiology 253:81-9. 2009
    ..To retrospectively assess the association between gadopentetate dimeglumine exposure at magnetic resonance imaging and the development of nephrogenic systemic fibrosis (NSF)...
  11. ncbi request reprint Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients
    Hani H Abujudeh
    Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Magn Reson Imaging 30:1335-40. 2009
    ..J. Magn. Reson. Imaging 2009;30:1335-1340. (c) 2009 Wiley-Liss, Inc...
  12. ncbi request reprint Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiency
    Jonathan Kay
    Rheumatology Unit, Massachusetts General Hospital, Boston, USA
    N Engl J Med 353:1605-13. 2005
  13. ncbi request reprint Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity
    Derrick J Todd
    Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Yawkey 2 174, 55 Fruit Street, Boston, MA 02114, USA
    Curr Rheumatol Rep 10:195-204. 2008
    ..In this report, we review the history of GASF, its association with prior GCCA exposure, its clinicopathologic features, the relevant pharmacology of GCCAs, the likely role of GCCAs in its pathogenesis, and potential treatments...
  14. ncbi request reprint Current status of nephrogenic systemic fibrosis
    L Daftari Besheli
    Radiology Department, Massachusetts General Hospital, Harvard Medical School, USA
    Clin Radiol 69:661-8. 2014
    ..The present review introduces and compares updated guidelines for GBCA use and discusses the latest advances in the understanding of the pathogenic mechanisms and treatment of NSF. ..
  15. pmc The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report
    Tuhina Neogi
    Boston University School of Medicine, Boston, Massachusetts, USA
    Arthritis Rheum 62:2582-91. 2010
    ..The aim of Phase 2 of the development process was to achieve expert consensus on the clinical and laboratory variables that should contribute to the final criteria set...
  16. ncbi request reprint Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts
    W F Owen
    Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts, USA
    Kidney Int 53:1365-73. 1998
    ..These findings support the hypothesis that beta 2m-AGE actively participates in connective tissue and bone remodeling via a pathway involving fibroblast RAGE, and at least one interposed mediator, the growth factor EGF...
  17. pmc Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention
    Sougata Karmakar
    Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, UMass Memorial Medical Center, Lazare Research Building, Suite 223, 364 Plantation Street, Worcester, MA 01605, USA
    Rheum Dis Clin North Am 36:385-404. 2010
    ..In this review, the authors discuss the current understanding of pathogenic mechanisms of bone erosion in RA and examine current therapeutic approaches to prevent this damage...
  18. ncbi request reprint Case records of the Massachusetts General Hospital. Case 4-2006. A 79-year-old woman with myalgias, fatigue, and shortness of breath
    Jonathan Kay
    Department of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, USA
    N Engl J Med 354:623-30. 2006
  19. doi request reprint Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial
    Stanley B Cohen
    Metroplex Clinical Research Center, Dallas, Texas 75235, USA
    Arthritis Rheum 58:1299-309. 2008
    ..The aim of this multicenter, randomized, double-blind, placebo-controlled, phase II study was to evaluate the effects of denosumab on structural damage in patients with rheumatoid arthritis (RA) receiving methotrexate treatment...
  20. ncbi request reprint Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen
    Jonathan Kay
    Cleve Clin J Med 75:112, 114, 117. 2008
  21. ncbi request reprint Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin
    Samuel L Moschella
    Department of Dermatology, Lahey Clinic, Burlington, Mass, USA
    N Engl J Med 351:2219-27. 2004